Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omburtamab radiolabeled therapeutic - Y-mAbs Therapeutics

Next Previous
Search
Drug Profile

Omburtamab radiolabeled therapeutic - Y-mAbs Therapeutics

Alternative Names: Hu8H9 - Y-mAbs Therapeutics; HuB7-H3 radiolabeled therapeutic - Y-mAbs Therapeutics

Latest Information Update: 12 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Mar 2023 huB7-H3 is still in preclinical trials for Solid tumours (In Adults) in USA
  • 30 Mar 2023 Y-mAbs Therapeutics has patent pending for B7H3 binding antibodies conjugated with chelators in the US , Europe, China and Taiwan as of March 2023
  • 30 Mar 2023 Y-mAbs Therapeutics has patent pending for new humanized B7-H3 binding antibodies in Taiwan, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, South Korea, New Zealand and the US as of March 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top